Shares of IMV Inc. (IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, have gained more than 20 percent over the last 5 trading days as the Company gears up to report topline results from its DeCidE1 trial on February 25, 2020.
DeCidE1 is an ongoing phase II study evaluating lead compound DPX-Survivac in patients with advanced recurrent ovarian cancer.
DPX-Survivac is designed to target Survivin, a tumor-associated antigen, is broadly over-expressed in most cancer types.
The primary endpoints of the study are overall response rate, disease control rate and safety. Secondary endpoints include cell mediated immunity, immune cell infiltration in paired biopsy samples, duration of response, time to progression, overall survival and biomarker analyses.
Ovarian cancer is the fifth most common cause of cancer mortality in women.
Last December, the Company presented updated results from SPiReL, an ongoing phase II investigator-sponsored study of DPX-Survivac in combination with Merck’s Keytruda in patients with recurrent/refractory diffuse large B-cell lymphoma (r/r DLBCL). The updated results showed that 7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses.
With just four days to go for the DeCidE1 trial results to be out, it’s worth keeping an eye on IMV.
IMV has traded in a range of $2.11 to $5.67 in the last 1 year.
Source: Read Full Article